Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892274) titled 'Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer' on Oct. 17.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition:
Metastatic Breast Cancer (MBC)
HER2-Positive Breast Cancer
Hormone Receptor-Positive Breast Cancer
Intervention:
Drug: Fulvestrant
Drug: Pyrotinib
Drug: Dalpiciclib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First...